Join to View Full Profile
753 Westport RdEaston, CT 06612
Phone+1 203-292-5516
Dr. Echols is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of New Mexico School of MedicineFellowship, Infectious Disease, 1977 - 1979
Newton-Wellesley HospitalResidency, Internal Medicine, 1975 - 1977
Tufts University School of MedicineClass of 1974
Certifications & Licensure
CT State Medical License 1992 - 2017
Clinical Trials
- A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis Start of enrollment: 2005 Dec 01
- A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media Start of enrollment: 2006 Jan 01
Publications & Presentations
PubMed
- 16 citationsActivity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014-2019.Mark G Wise, James A Karlowsky, Meredith A Hackel, Miki Takemura, Yoshinori Yamano
Microbial Drug Resistance. 2023-08-01 - 14 citationsProspective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.Marin Kollef, Herve Dupont, David E Greenberg, Pierluigi Viale, Roger Echols
International Journal of Antimicrobial Agents. 2023-08-01 - 12 citationsIn vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens ver...Christian M Gill, Debora Santini, Miki Takemura, Christopher Longshaw, Yoshinori Yamano
The Journal of Antimicrobial Chemotherapy. 2023-04-03
Journal Articles
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016...Roger Echols, MD, International Journal of Antimicrobial Agents
- Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacteria...Barry I Eisenstein, Roger M Echols, Clinical Infectious Diseases
Authored Content
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015November 2018
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against a Recent Collection of Clinically Relevant Carbapenem-Nonsusceptible Gram-Negative Bacilli, Including Serine Carbapenemase- and Metallo-Β-lactamase-Producing Isolates (SIDERO-WT-2014 Study)October 2018
Press Mentions
‘I Left the Pharmacy and Sat in My Car and Cried’: Soaring Insulin Prices Force Patients to Go Without or Ration DrugsJanuary 9th, 2019
Pharma Cash Flows to Doctors for Consultant Work Despite ScrutinyJanuary 3rd, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
